Skip to main content
KOBAYASHI PHARMACEUTICAL CO.,LTD. logo

KOBAYASHI PHARMACEUTICAL CO.,LTD. — Investor Relations & Filings

Ticker · 4967 ISIN · JP3301100008 LEI · 529900WBSL04KD6TKP95 T Manufacturing
Open in API
Filings indexed 74 across all filing types
Latest filing 2024-08-08 Legal Proceedings Report
Country JP Japan
Listing T 4967

About KOBAYASHI PHARMACEUTICAL CO.,LTD.

https://www.kobayashi.co.jp/english/

Kobayashi Pharmaceutical Co., Ltd. is a company engaged in the development, manufacturing, and marketing of a wide range of consumer products. Its core business segments include over-the-counter (OTC) pharmaceuticals, health and personal care items, and household goods. The company's diverse product portfolio features items such as nutritional supplements, deodorizing air fresheners, and disposable body warmers. Kobayashi Pharmaceutical focuses on creating innovative and niche products designed to solve specific, everyday problems for consumers, reflecting its brand slogan, 'You make a wish and we make it happen'.

Recent filings

Filing Released Lang Actions
訂正臨時報告書
Legal Proceedings Report Classification · 1% confidence The document is titled "訂正臨時報告書" (Corrected Extraordinary Report) and explicitly states it is being filed pursuant to Article 24-5, Paragraph 4 of the Financial Instruments and Exchange Act and related Cabinet Office Ordinance provisions (企業内容等の開示に関する内閣府令). This structure and purpose strongly indicate a filing required outside of regular periodic reports, typically classified as an Extraordinary Report or Timely Disclosure. In the provided schema, the closest fit for a comprehensive, non-periodic, material event disclosure is often captured under general Regulatory Filings (RNS) or sometimes specific event types. However, given the context of Japanese regulatory filings, '臨時報告書' (Extraordinary Report) is a specific type of timely disclosure. Since there is no specific code for 'Extraordinary Report' (like an 8-K equivalent), and this is a detailed report on a significant event (product recall/health issues) rather than just an announcement of a report's publication (RPA), it falls best under the general 'Regulatory Filings' category (RNS) as a catch-all for specific regulatory disclosures not covered by other codes, or potentially 'LTR' if the event involved significant legal/regulatory action, but RNS is safer for general timely disclosures. Reviewing the definitions, 'RNS' is defined as 'General regulatory announcements and fallback category for miscellaneous filings that do not neatly fit into other specific categories.' This document is a formal, mandatory regulatory filing detailing a material event (product recall and associated losses). Given the options, RNS is the most appropriate fallback for a specific Japanese regulatory filing type not explicitly listed (like a standard 8-K or a specific Japanese equivalent). Crucially, the document length is 1394 characters, which is short, but it contains the full details of the event, financial impact, and the basis for filing, making it the report itself, not just an announcement of a report (RPA). Therefore, RNS is selected.
2024-08-08 Japanese
臨時報告書
Board/Management Information Classification · 1% confidence The document is titled "臨時報告書" (Extraordinary Report) and is submitted to the Kinki Local Finance Bureau. Section 1, "提出理由" (Reason for Submission), explicitly states that the report is filed based on Article 24-5, Paragraph 4 of the Financial Instruments and Exchange Act, due to a resolution made at an extraordinary board meeting regarding a change in the Representative Director. Section 2 details the names, dates, and new/old positions of the departing and incoming Representative Directors. This content directly corresponds to the definition of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management.
2024-07-23 Japanese
確認書
Report Publication Announcement Classification · 1% confidence The document text contains the header "第１四半期報告書" (First Quarter Report) and specifies the period covered: "第107期第1四半期（自2024年1月1日 至2024年3月31日）". It also includes confirmation statements regarding the appropriateness of the report's contents, referencing the Financial Instruments and Exchange Act ("金融商品取引法"). This structure is characteristic of a comprehensive quarterly financial report in Japan, which corresponds to the definition of an Interim/Quarterly Report (IR). The document length is very short (600 chars), but the content is the substance of the report confirmation, not just an announcement of its availability, making IR the most appropriate classification over RPA or RNS.
2024-05-15 Japanese
四半期報告書－第107期第1四半期(2024/01/01－2024/03/31)
Interim / Quarterly Report Classification · 1% confidence The document is a 'Quarterly Report' (四半期報告書) for Kobayashi Pharmaceutical Co., Ltd. for the first quarter of the 107th fiscal period (January 1, 2024, to March 31, 2024). It contains detailed financial statements, including the consolidated balance sheet, and is filed in accordance with the Financial Instruments and Exchange Act of Japan. As it is a comprehensive financial report for a period shorter than a full fiscal year containing substantive financial data, it is classified as an Interim/Quarterly Report. Q1 2024
2024-05-15 Japanese
臨時報告書
Legal Proceedings Report Classification · 1% confidence The document is explicitly titled "臨時報告書" (Extraordinary Report or Timely Disclosure Report) in the header and in the '提出書類' (Filing Document) field. It is submitted to the Kinki Local Finance Bureau Director ('近畿財務局長') on May 10, 2024, citing Article 24-5, Paragraph 4 of the Financial Instruments and Exchange Act. The content details a significant event (the red yeast rice health issue) and quantifies the immediate financial impact (special losses recorded in Q1). This structure and purpose align perfectly with a mandatory, timely disclosure filing in Japan, which is best categorized as a general Regulatory Filing (RNS) or potentially a specific type of disclosure not explicitly listed, but RNS serves as the best fit for mandatory, non-periodic, significant event disclosures that aren't standard reports (like 10-K or IR). Given the options, RNS is the most appropriate general regulatory filing category for a timely disclosure of a material event.
2024-05-10 Japanese
臨時報告書
Regulatory Filings Classification · 1% confidence The document is titled "臨時報告書" (Extraordinary Report/Timely Disclosure Report) and is submitted to the Kinki Local Finance Bureau. The filing reason explicitly states that it is submitted based on Article 24-5, Paragraph 4 of the Financial Instruments and Exchange Act and Article 19, Paragraph 2, Item 3 of the Cabinet Office Ordinance on Disclosure of Corporate Information. The content details the establishment of a new subsidiary in Thailand, including its name, address, capital, and the date of the change (January 19, 2024). This structure—a formal, mandatory disclosure triggered by a specific corporate event (subsidiary establishment affecting ownership thresholds) under Japanese financial regulations—is characteristic of a timely disclosure filing. In the provided schema, the closest general category for mandatory, non-periodic regulatory disclosures that don't fit specific categories like 10-K, ER, or DIV is 'Regulatory Filings' (RNS). While it relates to capital structure changes, it is primarily a disclosure of a significant corporate event mandated by law, making RNS the most appropriate general classification among the options, as it is not a standard quarterly/annual report or a specific financing announcement (CAP). Given the document length is short and it is a formal regulatory filing, RNS is selected.
2024-05-02 Japanese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.